Get the Stockscreener App
7.9048
2.17%
-0.1752
Biohaven Ltd stock is traded at $7.9048, with a volume of 2.38M.
It is down -2.17% in the last 24 hours and down -52.55% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$8.08
Open:
$8
24h Volume:
2.38M
Relative Volume:
0.73
Market Cap:
$833.63M
Revenue:
-
Net Income/Loss:
$-766.97M
P/E Ratio:
-1.032
EPS:
-7.66
Net Cash Flow:
$-646.43M
1W Performance:
-4.30%
1M Performance:
-52.55%
6M Performance:
-59.79%
1Y Performance:
-83.75%
1-Day Range:
$7.81
$8.18
1-Week Range:
$7.48
$8.77
52-Week Range:
$7.48
$49.56
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
7.88 | 855.31M | 0 | -766.97M | -646.43M | -7.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.10 | 110.25B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.15 | 73.04B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.31 | 59.98B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
902.57 | 54.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
195.38 | 40.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Why hedge funds are buying Biohaven Ltd. stockGold Moves & Detailed Earnings Play Alerts - newser.com
Can Biohaven Ltd. stock resist sector downturns2025 Year in Review & Low Drawdown Momentum Ideas - newser.com
How Biohaven Ltd. stock benefits from global expansionWeekly Trade Report & Verified Technical Trade Signals - newser.com
How Biohaven Ltd. Common Shares stock trades in high volatilityM&A Rumor & Growth Oriented Trade Recommendations - newser.com
Biohaven closes upsized public offering, raises $200 million By Investing.com - Investing.com Nigeria
Biohaven Ltd. Raises $200M in Public Offering - TipRanks
Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M - PR Newswire
Biohaven (BHVN): Citigroup Lowers Price Target, Maintains Buy Ra - GuruFocus
Ropes & Gray Advised Underwriters in $175 Million Public Offering for Biohaven Ltd. - Ropes & Gray LLP
Building trade automation scripts for Biohaven Ltd.Weekly Gains Summary & Smart Investment Allocation Tips - newser.com
Biohaven Announces Pricing of $175 Million Public Offering of Common Shares - Eastern Progress
Will Biohaven Ltd. stock reach Wall Street targets2025 Stock Rankings & Real-Time Chart Pattern Alerts - newser.com
What Fibonacci levels say about Biohaven Ltd. reboundPortfolio Return Summary & Daily Entry Point Trade Alerts - newser.com
Strategic Focus and Financial Positioning Drive Buy Rating for Biohaven Ltd. - TipRanks
Biohaven price target lowered to $14 from $28 at Citi - TipRanks
Will Biohaven Ltd. stock remain a Wall Street favoriteEarnings Growth Summary & Entry Point Strategy Guides - newser.com
Biohaven prices $175 million public offering of common shares By Investing.com - Investing.com Nigeria
Is Biohaven Ltd. stock vulnerable to regulatory risksMarket Growth Review & Free Community Consensus Stock Picks - newser.com
Biohaven Ltd. (BHVN) Gets a Hold from Bank of America Securities - The Globe and Mail
Earnings visualization tools for Biohaven Ltd.2025 Price Targets & Weekly High Return Opportunities - newser.com
Biohaven Q3 Earnings: Falling Back To Earth With A Thud (NYSE:BHVN) - Seeking Alpha
What drives Biohaven Ltd stock priceRelative Strength Index (RSI) & Easy Tools to Analyze Your Investment Risk - earlytimes.in
Biohaven’s Secondary Offering Sparks Concerns Amid Regulatory Setbacks - timothysykes.com
Biohaven slumps on pricing $175 mln stock deal - TradingView
FLEX LNG, Biohaven And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why Biohaven Ltd. stock is favored by pension fundsQuarterly Risk Review & Daily Chart Pattern Signal Reports - newser.com
Biohaven (NYSE: BHVN) prices 23,333,334-share public offering for $175M gross proceeds - Stock Titan
Biohaven announces $150 million common shares public offering By Investing.com - Investing.com Canada
Biohaven Ltd. Reports Q3 2025 Financial Results - TipRanks
Biohaven slumps after $150 mln stock sale plans announced - TradingView
Biohaven announces $150M common share offering - TipRanks
Biohaven Launches $150 Million Offering of Common Shares - MarketScreener
Biohaven announces $150 million common shares public offering - Investing.com
Biohaven stock falls after $150 million public offering announcement By Investing.com - Investing.com Canada
Biohaven stock falls after $150 million public offering announcement - Investing.com
Biohaven announces proposed public offering of common shares - MarketScreener
Biohaven (NYSE: BHVN) commences $150M underwritten public offering; $22.5M option - Stock Titan
Is a relief rally coming for Biohaven Ltd. holders2025 Momentum Check & Weekly Breakout Watchlists - newser.com
William Blair reiterates Market Perform rating on Biohaven stock after FDA CRL - Investing.com Australia
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):